Testing an immunotherapy drug for advanced melanoma or kidney cancer
Part of Cancer, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a new drug called Cardonilmab for people with advanced melanoma or kidney cancer who have already tried other treatments. The goal is to see if the drug is safe and helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced melanoma or kidney cancer that has spread, and you have already tried at least two earlier treatments.
- You have at least one tumor that can be seen on a scan.
- You are physically able to care for yourself (ECOG score 0-2).
- Your major organs (heart, liver, kidneys, blood) are working well enough according to blood tests and heart checks.
- You are not pregnant or breastfeeding, and if you could become pregnant, you use effective birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests two new drugs (cadonilimab and anlotinib) for people with melanoma that has spread or grown after their first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
Hear when a new Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.